American Kidney Fund adds new corporate members to funding, development program
Click Here to Manage Email Alerts
The American Kidney Fund inducted four new members into the 2021 class of its corporate membership program.
The new additions include AstraZeneca and Vertex Pharmaceuticals as patron members, Dicerna Pharmaceuticals as an advocate member and Reata Pharmaceuticals Inc. as a friend member.
“We are proud to welcome the newest 2021 Corporate Members in our program and are grateful for their commitment to improve the lives of Americans living with and at risk for kidney disease,” AKF President and CEO LaVarne A. Burton said in a press release.
The corporate membership program provides thousands of dollars in funding for educational programming and resource development geared toward helping patients with kidney disease.
The 2021 class comprises 23 members including Amgen, Horizon Therapeutics plc, Quest Diagnostics Inc. and Pharmaceutical Research and Manufacturers of America.
“Our corporate membership program provides AKF with funding that is indispensable as we work with and for patients, caregivers, living organ donors and health care providers in the fight against kidney disease,” Burton said.
The corporate membership program of the AKF is open to new members interested in fighting kidney disease.
Read more about
Click Here to Manage Email Alerts